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RÉSUMÉ
Le resvératrol (3,4’ ,5-trihydroxystilbène) est un phytoalexine synthétisé par
certaines plantes suite à une infection fongique ou une irradiation aux rayons
ultraviolets. Le resvératroÏ existe sous deux formes, soient les isomères cis- et trans
resvératrol. Parmi sa vaste gamme d’effets thérapeutiques potentiels, le trans
resvératrol semble inhiber la réplication du virus de l’herpès simplex (HSV), ce qui
pourrait potentiellement en faire un traitement efficace contre les infections
chroniques d’herpès. Le premier objectif de ce mémoire était de caractériser la
pharmacocinétique du trans-resvératrol chez les lapins, suite à l’application topique
de deux crèmes contenant du trans-resvératrol. Le second objectif était de prédire
par allométrie la dose topique à administrer chez l’humain.
Les concentrations plasmatiques observées de trans-resvératrol après
l’application des deux crèmes indique que le trans-resvératrol diffuse à travers les
différentes couches de la peau jusqu’a l’épiderme basal, là où la réplication du virus
de l’herpès a lieu. Au total, 24 lapins ont reçu des doses topiques multiples de crème
contenant 12.5% ou 19.0% de trans-resvératrol pendant 28 jours consécutifs. Des
analyses pharmacocinétiques noncompartimentales et compartimentales ont été
réalisées à partir des concentrations plasmatiques de trans-resvératrol. L’analyse
compartimentale a été faite avec le logiciel Adapt II® pour l’analyse individuelle et
avec IT2S® pour les analyses de population. La biodisponibilité relative des deux
formulations a été évaluée avec les paramètres pharmacocinétiques obtenus par les
méthodes noncompartimentale et compartimentale de population. Les concentrations
plasmatiques du trans-resvératrol en fonction du temps ont été décrites par un modèle
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à un compartiment avec deux pics d’absorption. La pharmacocinétique du trans
resvératrol suite à une application topique est caractérisée par une clairance élevée et
une cinétique de type ‘flip-flop’.
Cette étude préclinique s’inscrit dans le cadre du développement d’un
traitement éventuel pour les infections au HSV chez l’humain. À partir des données
obtenues chez 3 espèces animales (souris, rat et lapin), les concentrations chez
l’humain ont été prédites par allométrie. Cette méthode a prédit une dose topique
efficace contre l’infection de l’herpès simplex chez l’humain de 292 mg de trans
resvératrol. Ainsi, suivant des doses topiques multiples de 300 mg, on obtient des
concentrations simulées chez l’humain pouvant aller jusqu’à 25 .tg/L. Ces
concentrations faibles obtenues par simulation pourraient soutenir l’hypothèse
courante dans la littérature selon laquelle certains conjugués du trans-resvératrol
possèdent également une activité pharmacologique. Les résultats de l’analyse
pharmacocinétique compartimentale et de l’allométrie présentés dans ce mémoire
pourraient être utiles dans le processus de développement préclinique et clinique
d’une formulation topique de trans-resvératrol.
Mots clés trans-resvératrol, topique, crème, pharmacocinétique,
noncompartimentale, compartimentale, population, allométrie
VSUMMARY
Resveratrol (3,4’,5-trihydroxystilbene) is a phytoalexin synthesized in certain
plants as a defense response to UV or fungal attack. It exists in both cis- and trans
resveratrol isomeric forms. In addition to its wide spectrum of potential therapeutic
effects, the inhibition of Herpes Simplex Virus (HSV) replication by trans-resveratrol
may provide an effective treatment against chronic herpes infections. The objectives
of this thesïs were to 1) characterize the pharmacokinetics of trans-reveratrol in
rabbïts after application of topical trans-resveratrol creams and 2) predict a topical
dose in humans using allometric scaling methodology.
Plasma trans-resveratrol concentrations observed after topical application of
both creams confirm that the compound was able to diffuse through the skin layers
and reach the basal epidermis, where active HSV replication occurs, and beyond.
Trans-resveratrol concentrations obtained from a total of 24 rabbits that received
multiple doses of either 12.5% or 19.0% trans-resveratrol cream for 28 consecutive
days were analyzed using noncompartmental methodology, individual compartmental
analysis (Adapt II®) and a population analysis (IT2S®). Comparative bioavailability
of each formulation was assessed and pharmacokinetic parameters were determined
using noncompartmental and population pharmacokinetic models. Plasma trans
resveratrol concentrations were best described by a Ï-compartment model with
double systemic absorption peaks. trans-Resveratrol pharmacokinetics after topical
application was characterized by a high clearance and “flip-flop” kinetics.
The long-term goal of this preclinical study is the eventual treatment of HSV
infections ïn humans. Allometric scaling from data obtained in 3 animal species
VI
(mouse, rat and rabbit) to human predicted that a 292 mg topical trans-resveratrol
efficacious dose would be required against HSV infection in humans. Simulations of
multiple topical 300 mg doses in humans would yield plasma concentrations up to
25 tg/L. These low predicted concentrations may support cunent hypotheses in the
literature that suggest possible pharmacological activity of trans-resveratrol
conjugates. Resuits of compartmental PK analysis and allometric scaling described
in this thesis may provide useful insight to provide optimal preclinical and clinical
drug development.
Keywords: trans-resveratrol, topical, cream, pharmacokinetic, noncompartmental,
compartmental, population, allometry
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ICHAPTER 1: INTRODUCTION
2Resveratrot
Resveratroi (3, 4’, 5-trihydroxystilbene) is a phytoalexin synthesized in
certain plants as a defense response to UV or fungal attack (Hammond-Kosack and
Jones 1996; Adrian et al. 2000). It exists in cis- and trans- resveratroi isomeric
forms, with or without a glucoside moiety, with the trans isomer exhibiting a higher
level of activity than its antipode (Figure 1.1). Resveratrol has been isoiated from
foods such as peanuts, soy, grapes and wïne as weii as from Itadori plant foots
(Potygonum cuspidatum) used for centuries in China and Japan as a traditional herbai
remedy (Burns et al. 2002). Interest in resveratrol by the scientific community was
sparked in 1992-93 when epidemiological studies demonstrated a decreased
incidence of cardiovascuiar diseases in Southem France even though dietary habits
typically included high amounts of saturated fat. This contradiction was coined the
“French Paradox”. The mild to moderate consumption of wine, specificaliy the
poiyphenolic compounds in red wine such as resveratrol, has been associated with
protective cardiovascular health benefits. Studies have since demonstrated additional
possible resveratrol antioxidant activities such as lipid oxidation prevention (Frankei
et ai. 1993), platelet aggregation inhibition (Pace-Asciak et ai. 1995), and modulation
of nitric oxide production (Hattori et ai. 2002).
HO
0H
Figure 1.1: Tue Structure of trans-Resveratroi
HO
3Initial publications of the potential beneficial cardioprotective effects of
resveratroÏ have been followed by an expanding list of potential benefits published
over the last decade. Briefty, these include extensive chemopreventive and
anticarcinogenic activities (Jang et al. 1997; Ciolino et al. 199$; Huang et al. 1999;
Park et al. 2001; Bhat and Pezzuto 2002), estrogenic properties (Gehm et al. 1997),
anti-inftammatory effects (Donnelly et al. 2004), the activation of life-extending
genes in yeast (Howitz et al. 2003) and the increased production of sperm in healthy
rats (Juan et al. 2005). Anti-viral effects have also been demonstrated against HIV
(Heredia et al. 2000) and the herpesviridae cytomegalovirus (Evers et al. 2004) and
herpes simplex HSV-1 and HSV-2 (Docherty et al. 1999; 2004).
Resveratrot effect on Herpes Simptex Virus
The inhibition of herpes simplex virus (HSV) replication by trans-resveratrol
may provide an effective treatment against chronic herpes infections. According to
the Center for Disease Control, 70-90% of the general population carry HSV-1 and as
many as one million are infected annually with HSV-2 in the United States (Fleming
et al. 1997). Neonatal herpes infections may be extremely virulent and are associated
with high mortality and morbidity. The most common transmission route is during
delivery (Parker and Montrowi 2004). Controlling HSV infections, predominantly
HSV-2, is highly desired due to its potential role as a co-factor in HIV transmission
(WHO 2001).
During initial infection, the herpes simplex virus is transported by retrograde
axonal transport to the nuclei of neurons near the local infection site (White and
Fenner 1994). The virus then establishes a cycle of latent infection in neurons
4followed by active replication occurring within 15 hours post infection in epithelial
cells surrounding the oral, eye and genital areas (Docherty and Chopan 1974; Jenkins
and Turner 1996). Thus, the virus has the ability to persist in its host indefinitely.
No known cure exists; however, treatments are available for cutaneous outbreaks
during active viral replication. Current treatments employ nucleoside analogues,
from which acyclovir (Zovirax®) is the earliest, and most tested, treatment (De
Clercq 2004). The mechanism of action involves acyclovir phosphorylation by viral
thymidine kinase, followed by incorporation into replicating DNA by viral DNA
polyrne rase. Acyclovir halts HSV replication through competitive inhibition and
inactivation of DNA polyrnerase and by preventing further addition of nucleotides to
the elongating DNA chain. Although acyclovir’s advantage is its high specificity for
HSV-infected cells due to its requirement of viral proteins for efficacy, its
dependence on viral proteins also increases the probability of developing HSV
resistant strains, which have indeed been isolated from immunocompromised
patients, prompting more research into alternative forms of therapy (NUA 2002).
Trans-Resveratrol’s inhibitory mechanism against HSV replication does not
depend on activation by viral proteins, nor does it inactivate HSV direct!y or inhibit
HSV entry into the ce!! in vitro (Docherty et al. 1999). Although the exact
mechanism of action has yet to be elucidated, Docherty et al. have demonstrated
resveratro! dose-dependent reversib!e inhibition of the cell cycle at the S-G2-M phase
in healthy celis as wel! as the inhibition of immediate early viral protein production
during the vira! replication cycle in vitro. This inhibition by trans-resveratrol of
regu!ar cellular events and of early viral events may contribute to the disruption of
the HSV replication cycle. In vitro trans-resveratrol concentrations of approximate!y
525-50 tg/rnL appear to be efficacious against HSV replication. Interestingly, trans
resveratrol inhibits production of the essential immediate early regulatory viral
protein ICP-4 required for HSV replication in epithelial (active phase) and neuron
(latent phase) celis. Thus, resveratrol may have the ability to prevent reactivation of
latent virus. This added potential therapeutic benefit is flot possible with nucleoside
analogue therapies because of their dependence on early viral enzymes produced only
during the active phase of viral replication in epithelial ceils.
Trans-Resveratrol efficacy in vivo was recently demonstrated on cutaneous
HSV- 1 infections in hairless mice (Docherty et al. 2004). Two creams containing
12.5% and 25% trans-resveratrol, as weIl as the 5% acyclovir ointment, were applied
to the infected area of approximately l-2 cm2 on the dorsal aspect of the neck at
various times after induced HSV cutaneous infection. Briefly, application of both
trans-resveratrol formulations resulted in a significant decrease in HSV lesion
formation compared to control, and with comparable efficacy to the 5% acyclovir
ointment. The most effective resuits were obtained when trans-resveratrol cream was
applied within 1-6 hours post infection, every 3 hours, 5 applications per day, for 5
days. There were no apparent indicators of dermal toxicity in the study animais at
these doses.
Topical administration of trans-resveratrot
The results above demonstrate that an efficacious concentration of trans
resveratrol appeared to have reached the site of active HSV replication at the basal
epidermis layer of the skin. After application of cream on the skin surface, trans
resveratrol must pass through the stratum corneum barrier and epidermis, presumabiy
6by a series of complex, as yet unknown, processes prior to reaching the basal
epidermis. Figure 1.2 illustrates the different layers in human skin.
Figure 1.2: The Structure ofHuman Skin
Hir tohcIe (foIIicuIii)
The skin is a multilayered membrane, which includes the stratum corneum,
epidermis and dermis layers. Trans-resveratrol’s diffusion across the stratum
corneum could be a rate limiting process to reaching the basal epïdermis. Studies
using human skin have shown that the topical application of acyclovir ointment is
less effective against HSV infection than oral or intravenous administration because
of acyclovir’s inability to efficiently penetrate the stratum corneum (Qureshi et al.
1998). The stratum corneum is an efficient barrier consisting of multiple lipid
bilayers and anucleate keratinocytes whose main functions are to regulate water loss
and halt entry of toxic materials (Williams 2003). Once cream is applied to the outer
layer of the skin, passive diffusion through the stratum corneum potentially begins
following water evaporatÏon from the cream, which increases the concentration
Source: http//www.images.MD/ Université de Montréal access
7gradient of trans-resveratrol solubilized in the formulation constituents, thereby
driving permeation. Formulation enhancers, such as propylene glycol, reduce the
skin barrier function aitering diffusivity of the active ingredient through the skin
(Smith et al. 1999). In addition, hydration of the stratum comeum will likely increase
the drug permeation process dependent upon the polarity of the permeant (Flynn
1993). On the other hand, evaporation upon application of the cream changes the ou
water partitioning resulting in a surface residue. The degree of precipitation may
compietely hait the drug delivery process.
The passage of trans-resveratrol through the stratum comeum layer is
followed by a partitioning step, then diffusion through the viable epidermis layer.
The viable epidermis has a higher water content and is composed of living cells
where contact may occur with metabolically active enzymes catalyzing phase I and
phase II reactions (Hotchkiss 1998). Enzyme activity by cytochromes P-450 phase I
enzymes such as CYP1A1, 1B1, 2B and 3A, and phase II enzymes such as UDP
glucuronosyltransferases and sulfotransferases has been observed in human skin,
albeit at lower levels in comparison to their activity in the liver. Cutaneous loss of
trans-resveratrol aglycone may be attributed to potential metabolism with these
enzymes. For example, the biotransformation of trans-resveratrol to the active
antileukemic agent piceatannol by CYPYB1 lias been reported (Potter et al. 2002), as
have conjugation reactions catalyzed by sulfotransferases (Yu et al. 2002) and
various UDP-glucuronosyltransferases (Aumont et al. 2001).
Trans-Resveratrol is systemically absorbed via capillaries found in the dermis
layer beneath the basal epidermis, the target area for topically applied trans
8resveratrol cream where active HSV infection occurs therefore, minimal systemic
exposure would be preferred.
Pharmacokinetic Approaches
Pharmacokinetic analyses may provide some insight into the fate of trans
resveratrol following topical application. Pharmacokinetics is generally defined as
the kinetic processes over time describing the absorption, distribution, metabolism
and excretion of a drug administered to an organism (Shargel and Yu 1999). PK
parameters are derived from observed drug concentrations, often obtained from blood
andlor urine, plotted against their sampling times. Pharmacodynamics (PD)
describes the desired physiological effect(s) of a drug at the site of action in the body,
the ‘biophase’. The biophase is often defined as the effect area surrounding the
receptor, which initiates a cascade of desired events when bound to the drug (Boume
and von Zastrow 2004; Gabrielsson et al. 2000). If equilîbrium is established
between the drug concentration in the systemic circulation and at the biophase,
therapeutic doses can be determined by measuring solely the drug concentration in
the blood necessary to obtain the desired drug effect (PKJPD correlation).
The biophase where trans-resveratrol inhibition of HSV replication is likely to
occur is in infected epithelial celis of the basal epidermis layer of the skin. Figure 1.3
is a simplified sketch of the potential movement of trans-resveratrol to the biophase
after topical application.
9Figure 1.3: trans-Resveratrol Biophase aizd Btood Coinpartinents in tize skin
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figure 1.3 Possible routes of trans-resveratrol movement through the skin, biophase (site of action),
and systemic circulation by absorption into the capillaries in the dermis layer of the skin. Theoretical
trans-resveratrol re-distribution between the systemic circulation and the biophase is shown by the
two-way movement between the blood and biophase “compartments”.
Since only PK rather than PD analyses were performed for this research, the
remaining introduction will focus on PK methodoiogy. There are two main
approaches used in PK analyses: 1) noncompartmental approach and 2)
compartmental approach.
Noncompartmental Approacli
The noncompartmental PK approach depends upon the foliowing
assumptions: Ï) the dmg follows linear first-order PK processes, 2) ail drug
molecules will be completely eliminated from the organism, and 3) the eiimination
process occurs from the samplïng compartment (usually the circulatory system)
(Gibaldi and Penier 1982). This approach is based largely on the area under the
curve (AUC) of the observed drug concentrations versus time (Figure 1.4).
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Figure 1.4 Basic example of concentration versus time profile used in
noncompartmental pharrnacokinetics
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The AUC can be estimated using the linear trapezoidal fuie (Gabrieisson and
Weiner 2000) as follows:
n
AUC0 = Z (C + C+1)/2 At + Ciastfkel
i=1
where C1 is the th concentration, Ciast is the last measurable concentration, At is the
discretïsation time interval t +i - t between concentrations and kel is the eiimination
rate constant. The AUC is dependent upon the number of biood samples where a
richer sampling will resuit in a more accurate approximation of the true AUC. If the
contribution at the last extrapoiated trapezoid is significant (e.g. 20% or greater), the
calculation of the AUC to infinity may not be considered robust. The AUC
parameter over a specific dosing interval can determine whether there is evidence of
drug accumulation following multiple doses under steady-state conditions. The
AUC0 calculated after a single dose should be equivalent to the AUC0 at steady
state, where ‘t represents the dosing interval. This relationship is based on the
AUC
Clast
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premise that the AUC0 and AUCo characterize the extent of exposure of each drug
molecule relative to the dose administered.
The AUC used in noncompartmental pharmacokinetics is derived by the
theory of statistical moments (LeBlanc 1997). This theory introduces the area under
the moments curve (AUMC) to describe the mean residence time (MRT) of a drug in
the sampling compartment. The MRT is therefore only really obtainable after
intravenous administration.
The following pharmacokinetic parameters may be determined using
noncompartmental analyses (Gibaldi and Perrier 1982):
Parameter Description
Maximum observed plasma drug concentration in the
Cmax
concentration versus time profile.
The area under the curve from O to the last measurable
AUCo concentration as determined by the linear or Iog-linear
trapezoidal rule.
The area under the moments curve defined as:
AUMC + t+1C+1)/2
where t1 = sampHng time, C1 = concentration and At = t i+i - t
MRT AUMC/ AUC — Duration infusion! 2
The elimination rate constant equivalent to the slope derived
Kel
using linear regression of the ln(concentration) versus time.
T½ The elimination haif-life defined by O.6931ke1.
The total apparent drug clearance defined by:
CLIF Dose! AUC0 (single dose) and
Dose! AUC0 (steady-state), where T is the dosing interval.
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Compartmental Approach
The compartmental pharmacokinetic approach is based on the assumption that
organisms are composed of a system of interconnected “weÏl-stirred” compartments
from which a finite number can be kinetically described in a mode! (Foster 2001).
Often one assumes that each drug molecu!e lias the same probability of transferring
to or from a compartment, and that this transfer is governed by first-order conditions
where the transfer rate of a drug molecu!e from one compartment to another is
proportional to its concentration within the original compartment. An examp!e is
il!ustrated in figure 1.5.
Figure 1.5 Two-Compartinent Pharinacokinetic Model
VpfF
I.V. Dose.
Linear PK mode!s are described for a given range of doses by nonlinear
regression mode!s that generally take the fo!!owing form: Y = Aet + Bet where A,
B, Œ, and f3 may be parameters estimated in a two-compartment mode!. After an
extravascu!ar dose such as p.o. administration, the drug dissolves in the gastro
intestinal “drug dissolution” compartment prior to being absorbed in the circulatory
Extravascular
Dose
Ka
Lag
CL
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system (Vc/F). The drug is immediately distributed into the circulatory system and
periphery (VpJF) and! or is irreversibly eliminated (CL) from the organism. After an
i.v. dose, the drug is immediately distributed into the circulatory system (Vc).
Parameter Estimation Procedure
The model-derived parameters attempt to describe the pharmacokinetic
behavior of the observed concentrations (Y) while minimizing the difference
between the observed and model-predicted concentrations (î).
Minimization Methods
Examples of minimization methods are presented below (Gabrielsson and
Weiner, 2000):
(1) Ordinary Least Squares: °OLS =
(2) Weighted Least Squares: °WLS =
(3) Extended Least Squares: OELS = Z [W(Y-’)2 + In(var(’))J
(4) Generalized Least Squares = stepi: QOLS
-2
step 2: OIYLS where Wt = var(OOLS) step j
where O is the objective function, Y is the observed concentration, is the model
predicted concentration and W is the applied weight. The applied weight may be the
inverse variance attributed to the observation. Thus, observations that are more
variable (less reliable) will theoretically contribute less to parameter estimation. The
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generalized least squares method may be used to overcome limitations when the error
variance is flot normally distributed.
Algorithms designed to choose the most optimal parameter estïmates using
maximum likelihood (ML) are available for nonlinear models. ML is used to
determine the most likely set of parameter estimates given the observed
concentrations. One of the most robust algorithms is the Nelder-Mead simplex
method (Gabrielsson and Weiner 2000). These complex computations require the
plotting of the weighted residual sum of squares (WRSS) of each parameter to form a
“simplex”. The goal of this algorithm is to minimize this simplex by a defined
criterion and select the optimal parameter solutions often called the “global
minimum”. Other less optimal solutions are referred to as “local minima”.
Model Discrimination Criteria
Various statistical methods are used to select the best mode! from a pool of
rival models. Specifically, these methods assess the goodness-of-fit of ah models to
a particular dataset and compare the statistical values. Examples of commonly
employed methods are presented below: (Gabrielsson and Weiner 2000):
(1) F-test
/ WRSS1 — WRSS2 /
F St(ltiStiC = Idf — (ff2 / > ftable (0.05; Adf df2)
/ WRSSJ
df2
where df = degrees offreedom calculated as: Nobs
-
Np
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The F-test is applied to compare hierarchica! models, where one mode! can be
deduced from the other (full versus reduced). The F distribution describes the
probability that adding more pararneters to a model will not change the WRSS.
Therefore the difference WRSS1 — WRSS2 is theoretically zero. If the F statistic
is greater than the Ftable then the model with additional parameters is considered
more appropriate.
(2) Akaike Information C’riterioit (‘AIC):
AIC = N)Ç hz(WRSS) + 2Np
where N0b is the number of observations in the dataset, WRSS is the weighted
residual sum of squares area or objective function, and Np is the number of
parameters used in the model. The model with the !owest AIC real number value
is generally deemed the most appropriate. The Np is added to the formula as a
penalty factor. A model with more parameters than another must justify their
inclusion by having a !ower WRSS by a quantified amount. Thus, if two models
have a different number of pararneters but similar AIC values, the model with the
lowest number of parameters will be judged the most appropriate mode! as
dictated by the !aw of Parcimony.
(3) Schwartz Criterion (SC)
SC = ln(WRSS) + Np Ïn(N(,bV)
This approach is based on the sarne princip!es as the AIC but with a stricter
penalty proportional to the ln-transformed number of observations in the dataset.
16
(4)Residuat Error or Variabitity Anatysis
Resid = [1ope + t5,zt/l1] X 100
where 1ope represents the siope of predicted versus observed values, the
intercept and t the mean concentration values (observed or predicted). The
residual variability is dependent on the variance model used and measures the
amount of variability that cannot be explained by the model. Thus, residual
variability is minimized.
(5) Estimation Criterioit Value (ECV)
The ECV is the objective function as calculated in the minimization methods
section above and is based on the WRSS, but without a penalty regarding the
number of parameters used in the model. The ECV may therefore be smaller, and
the AIC higher for models with a comparatively higher number of parameters for
example, since the number of solutions available to the model is theoretically
increased. Thus, a better fit may resuit in physiologically meaningless
parameters. The ECV should be minimized with the caveat that the model with
the lowest value may flot be the most appropriate.
(6) Coefficient ofDetermination (R2)
R2 = 1
— Z (YHi -iti2
i=1 Wi
(Yiti)2
-
(Y ti )2
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where ‘i is the predicted value, ti is the corresponding sampling time and Y is the
average of the observed values. A model that perfectly predicts the observed
concentrations would yield a coefficient of determination equal to 1.
Population Pharmacokinetics
Population compartmental pharmacokinetic models attempt to describe the
behavior of a drug in a target population with the aim of applying the model to
individuals with similar characteristics (Jelliffe et al. 2002). Population PK
parameters quantify 1) population mean kinetics, 2) inter-individual variability, and
3) intra-individual variability, assay error, and model error (Sheiner and Beal 1983).
The population method is more advantageous than individual compartmental
estimates because it more robustly assesses the residual error (point # 3). One can
therefore attempt to explain the variability observed in patients with cofactors such as
age and hepatic function, which may affect the PK behavior of a drug.
Two approaches to population modeling are: 1) Parametric and 2) Non
parametric.
Parametric
The parametric approach assumes the population parameters follow a known
distribution, most commonly normal or log-normal (Jelliffe et al. 2000). One risk of
assuming a normal distribution is flot identifying subpopulations from which
characteristics such as gender, age or smoking habits may affect the PK of a drug.
PK parameters are estimated by measuring central tendency such as the mean or
median. The two main approaches for estimating population parameters are the two
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stage methods, (for instance the standard two-stage (STS), iterated two-stage (ITS)
and global two-stage (GTS) methods) and one-stage nonlinear mixed effect modeling
(NONMEM) method.
Standard Two-Stage (STS)
This two-stage method first fits the individual data, and then population
estimates are derived in a second step. The STS method derives the population
estimates by providing descriptive statistics of PK parameters (i.e. average, standard
deviations and correlation coefficients) of each parameter.
Iterated Two-Stage (ITS)
The ITS method begins by following the steps outlined for the STS method,
then continues the analysis by comparing the parameter estimates to each patients’
maximum ci posteriori probability (MAP) (Jelliffe et al. 2002). Following this initial
cycle, the parameter estimates may be used as priors to estimate new parameters and
calculate new population means. This cycle continues iteratively until parameter
convergence is obtained. The parameters and correlation coefficients are used at
various intervals of the iterative process to measure the variance parameters ci
postenon. The IT2S® software uses this method.
Noittinear Mixed Effects Modeting (NONMEM)
Developed by Sheiner and Beal (Sheiner and Beal 1980), NONMEM is a
widely used software that is very useful in, but not limited to, clinical environments
where very sparse nonhomogeneous data collection often occurs. It is defined as a
19
one-stage approach because individual parameter estimates are flot requïred and the
dataset is analyzed globally. Individual PK parameters can also be provided in a post
hoc analysis. The global goodness-of-fit is assessed by the objective function value
based on the estimated parameters fitted by the extended least-squares minimization
method. A decrease in the objective function value determines a better global fit.
Advantages to using NONMEM include the addition of covariates such as creatinine
clearance to explain inter-individual variability between patients, the use of a
nonhomogeneous dataset obtained from patients in different clinical settings and
model determination based on very sparse data from a specific patient population
with applications for therapeutic drug monitoring.
Non-Parametric
The non-parametric approach does flot make any assumptïons regarding
population parameter distributions. Ail model parameters are estimated for each
subject and the probability of obtaining those parameters based on the observations is
also estimated for each subject. Thus, this approach may be useful to identify any
subpopulations that may be missed using parametric methods. Two widely used
methods are the Nonparametric Maximum Likelihood (NPML) and Nonparametric
Expectation Maximizing (NPEM) methods.
A comparison of the advantages and disadvantages of the different pharmacokinetic
modeling strategies is tabulated below.
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Table 1.] Comparisons ofNoncompartrnental and CornpartrnentaÏ FKApproaches
Noncompartmental PK Compartmental Compartmental
Individual PK Population PK
Advantages - Rapid - Drug may follow - Drug may follow
- Simple linear or non-linear linear or non-linear
PK PK
- Robust
- Accommodates all - Accommodates ail
- Independent of the
routes of drug routes of drug
anaiyst; model
. administration administrationdetermmation steps
flot required - Moderately sparse - Sparse, very sparse
sampiing conditions nonhomogeneous
- May provide insight sampiing conditions
into the PK activity of - Intra-individual
the drug variability estimated;
- Mechanistic model residual variability
linking PK and PD estimation more
possible robust
- Model simulations - May identify
covariates
contributing to
parameter variability
- Mechanistic mode!
linking PK and PD
possible
- Dose determination
in patients;
therapeutic drug
monitoring
Disadvantages - Certain parameters can - Time consuming:
- Time consuming:
only be determined for mode! determination model determination
IV drug administration process and analyses process and analyses
- Requires rich sampling - Complicated
- Complicated
- One compartment - PK parameters flot
approach robust; high variabiiity
- PK parameters
- intra-individual
dependent on the variability not
sampling scheduie computed
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Pharmacokinetic Modeling
Pharmacokinetic models are important because they reduce the mechanical
complexity of drug kinetics in organisms to a more simplified form. This selective
representation of reality has concrete applications such as predicting therapeutic dose
ranges for a patient or estimating parameters flot measurable in vivo, such as the
absorption rate constant (Boxenbaum 1992). The decision to use noncompartmental
versus compartmental modeling depends upon the specific type of knowledge desired
from the data and the appropriateness of the method to obtain that knowledge (Foster
2001). Thus, noncompartmental and compartmental PK approaches can complement
each other in acquiring pharmacokinetic information about a drug. As outlined in
Table 1.1, the advantages and disadvantages of each method may dictate the best
approach for answering specific questions about the data.
Trans-Resveratrol Pharmacokinetics
There are no known topical trans-resveratrol pharmacokinetic studies
published in the literature. However, the PK behavior of oral and i.v. trans
resveratrol administered to laboratory animals and humans has been studied over the
last decade and a brief overview of some of those resuits is presented. Trans
Resveratrol appears to be well absorbed after oral administration and highly
metabolized to glucuronide and sulfonide conjugated forms, with resveratrol-3-
sulfate being the primary conjugation metabolite in humans (Yu et al. 2003). Trans
Resveratrol was identified as a moderate inhibitor of CYP 3A4 and weak inhibitor of
CYP 2C19. However, the sulfate metabolite was flot an inhibitor of any of the CYP
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enzymes used in the study. Oral (25 mg) and i.v. (0.2 mg) administration of
[‘4Clresveratrol to humans revealed three potential metabolic pathways including
extremely rapid sulfate conjugation, glucuronic acid conjugation and hydrogenation,
the latter, accordïng to the authors, possibly produced by intestinal microflora (Walle
et al. 2004). In addition, trans-resveratrol accumulation was observed in epithelial
ceils of the aerodigestive tract. Urine excretion appeared to be predominant,
accounting for 53-85% of the oral dose and 42
— 83% after intravenous dose;
recovery in feces reached 38% and 23%, respectively, and also contained the major
resveratrol sulfate conjugate. Secondary peaks in the trans-resveratrol concentration
profiles were attributed by the authors to enterohepatic cycling (EHC). Convincing
evidence of its occurrence in rats has been demonstrated in a linked-rat model
(Marier et al. 2002). The absorption of trans-resveratrol in the Walle study was high,
about 70%, while the bioavailability was negligible which correlated with other
published in vivo preclinical results (Andlauer et al. 2000; Kuhnle et al. 2000; Meng
et al. 2004). In one study, the absolute bioavailability of trans-resveratrol in rabbits
was approximately 1.5% and the elimination haif-life was estïmated to be 15 minutes
following i.v. administration (Asensi et al. 2002). Preferential accumulation of
radiolabeled trans-resveratrol and conjugates in mice occurred in the stomach, liver,
kidney and intestinal tissues, as well as in the bile and urine (Vitrac et al. 2003).
Low trans-resveratrol bioavailability reported in many species, including
humans, lias resulted in speculation about the availability, and therefore possible
desired biological activity, of non-metabolized trans-resveratrol. Efficacy lias been
reported at doses whicli would normally produce plasma levels below the 10 —
100 iM range apparently required for in vitro activity (Gescher and Steward 2003).
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There appears to be a general consensus in the literature regarding this discrepancy
between in vitro activity and in vivo bioavailability and the need to determine
whether trans-resveratrol’s in vivo pharmacological activity can also be attributed to
its conjugates.
Allometry
Although the primary purpose of preclinical studies is to characterize the
safety of a potential drug, preclinical studies are increasingly used to predict a drug’s
efficacious dose and pharmacokinetic behavior prior to dosing in humans. Allometry
is one method used for this purpose.
Allometry is based on the fact that mammals of different sizes live for
approximately the same amount of biological time. Since mammals breathe once
every four heartbeats, approximately 200 million breaths and $00 million heartbeats
are expected in a typical lifetime (Gould 1979). The relationship is characterized as
follows:
Breath time = 0.000047OEBW°28
=4.02
Heartbeat time = 0.0000 1 19BW°’25
where BW is the body weight. Many biological characteristics such as blood flow
rate, size of capillaries, lung volume, etc., are functions of body weight (Calabrese
1984). Parameters that are a function of body weight and that also affect the PK of a
drug may be predicted by allometric relationships across species. This premise is the
basis for scaling preclinical pharmacokinetic parameters to humans.
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The allometric method uses a power function Y = aWb, which becomes a
linear equation when plotted on a logarithmic scale: log(Y) = log(a) + blog(W)
where
Y = parameter of interest
W Body weight
a = coefficient or intercept of the une
b = exponent or siope of the une
Figure 1.6 is a generic example of an allometric scaling across species for a particular
parameter. The allometric relationship is defined by the equation of the straight une
derived by linear regression analysïs. The regression une is generally extrapolated to
a 70 kg weight for humans.
Figtcre 1.6: Graphic Representation ofAlloinetric Scaling
Human
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0.01 0.1 1 10 100 1000
Weight (kg)
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Objectives
There are two main objectives of the research described in this thesis:
1) Characterize the pharmacokinetics of two trans-resveratrol topical
formulations after multiple topical applications to rabbits. Specifically, the
bioavailability of each formulation is assessed and pharmacokinetic
parameters are determined using noncompartmental and population
pharmacokinetic models.
2) The long-term goal of these preclinical studies is the eventual treatment of
HSV infections in humans. Therefore, an efficacious topical dose in humans
is estimated via allometric scaling analyses using preclinical data in rabbits,
as well as data from the literature.
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CHAPTER 2: METHODOLOGY
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Prectinicat Study Design
Thirty New Zealand White Rabbits (15 males and 15 females) were divided
ïnto 4 primary groups, with one phase of the fourth group for toxicokinetic (TK)
evaittation. The dose of trans-resveratrol cream applied for each treatment in each
group is described in Table 2.1.
Table 2.] - Quantity oftraizs-resveratrol cream applied per group:
Group Quantity of Formulation trans-Resveratroi Number of Animais
Cream trans- Dose
Applied Resveratroi Applied Primary TK
(mg) ( %) (mg)
1* 66 0 0 6 -
2 4 12.5 0.5 6 -
3 20 12.5 2.5 6 -
4 66 19.0 12.5 6 6
* Group 1 — Control group flot included in the pharmacokinetic analyses.
An appropriate area on the upper dorsum was clipped free of haïr close to the
skin the day before the start of treatment and was carefully re-clipped or shaved with
an electric razor as deemed appropriate throughout the study. A non-occluded dose
of cream containing either 0%, 12.5% or 19.0% trans-resveratrol was applied using a
gloved finger to a 4 cm2 area approximately every 2 hours, 5 times per day, for 28
consecutive days. Gloves were changed between each group of animaIs. The
number of treatments applied per day was based on previous efficacy studies of
topical trans-resveratrol cream against HSV in a mouse model (Docherty et al. 2004).
In addition, multiple applications per day followed by a long period without a dose
(while asleep) mimic a standard topical treatment for HSV infections in humans.
There were no apparent signs of toxicity or adverse dermal reactions at the dose
levels tested in this study.
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On Study Day 10, a change in washing procedure between doses was
initiated. It appeared that the residue left over from a previous dose was flot
adequately removed after wiping the area with water. Therefore, a mild soap was
also used for the remainder of the study. The addition of soap to the washing
solution could have facilitated trans-resveratrol’s diffusion across the skin layers by
extracting lipids from the stratum corneum, which is known to decrease its barrier
properties (Pugh 1999). Thus, there is a possibility that a lower amount of trans
resveratrol was absorbed into the systemic circulation after the first dose on Day 1
through to Day 9 compared to the amount absorbed after Day 10. However, a relative
bioavailability factor did flot improve the overail quality of fit in the population
pharmacokinetïc analyses (results flot shown).
Blood samples were obtained from the central ear artery at the nominal times
outlined in Table 2.2 below:
Table 2.2 — Pharmacokinetic Sainpling Schedute
Sampling Schedule (h)
Formulation Primary Phase TK Phase
Groups (% trans- Dose Days 1 & 28 Days 1 & 2$ Day 14
resveratrol) (mg) 0, 0.5, 2 0, 0.25, 0.5, 0.75, 1, 1.5, 2 0, 0.5, 2
2 12.5 0.5
3 12.5 2.5
4 19.0 12.5 q q
Blood samples for groups in the primary phase were obtained on Days 1 and
28 before the first application of cream (0-hr) and at 0.5 and 2 hours thereafter.
Blood samples were obtained for Group 4, TK phase at predose (0-hr) and at 0.25,
0.5, 0.75, 1, 1.5 and 2 hours postdose on Days 1 and 28, as well as at predose (0-hr)
and at 0.5 and 2 hours postdose on Day 14.
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Table 2.3 presents labels used throughout this thesis to reference the specifïc
dose groups and formulations.
Table 2.3 — Animal dose group and formulation labels
trans- formulation CorrespondingGroup DosePhase Resveratrol (% trans- FormulattonNo. GroupDose (mg). Resveratrol) No.
2 0.5 Low 12.5 I
Primary 2.5 Mid 12.5 I(n= 18)
4 12.5 High 19.0 II
TK 4 12.5 1K 19.0 II(n =6)
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ExtrapoÏated trans-resveratrol Concentrations
Plasma trans-resveratrol was measured using a validated LC/MS/MS method,
developed at MDS Pharma services, with a lower limit of qtiantification (LLOQ) of
4 ng/mL, an upper limit of quantification (ULOQ) of 1000 ng/mL, and a lower iïmit
of detection (LLOD) of 1 nglmL.
An aliquot of rabbit plasma containing the anti-coagulant EDTA, trans
resveratrol and the internai standard naringenin was extracted using a protein
precipitation extraction procedure. The extracted sampies were analyzed by high
performance liquid chromatography equipped with an MDS Sciex mass
spectrometer. Quantitation was by peak area ratio. Precision (%CV) and accuracy
(%Theoretical) calculations for the quality control samples were less than 10% and
11%, respectively, which met the 15% acceptance criteria. Similarly, precision and
accuracy resuits for LLOQ validation sampies were 12.7% and 0.5% (inter-batch)
and 17.9% and 3.0% (intra-batch), respectively, which satisfied the 20% acceptance
criteria.
This study was the first to be performed in rabbits, therefore, there was a
possibiiity that the predicted trans-resveratrol concentrations would flot be observed
at the administered doses. Indeed, only 44% of the blood samples were initially
available for pharmacokinetic analyses because the remaining 56% were reported as
below the LLOQ (BLQ). Since lowering the LLOQ was not possible, the
concentrations between the LLOQ of 4 ng/mL and the LLOD of 1 ng/mL were
extrapoiated. The quantity of available samples was therefore increased to 75% and
these extrapolated concentrations were included in ail of the pharmacokinetic
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analyses, however because they are flot associated with the same certainty as the
concentrations above the LLOQ, they were fitted with a separate variance mode!.
The analyticai instrument had a lower sensitivity for calculating concentration
values between the LLOD and LLOQ; consequently, it was assumed that
extrapolated concentrations were more variable. for compartmentai pharmacokinetic
analyses, the variability associated with extrapolated concentrations was calcuiated
separately; however, the weighting method was identicai for ail concentrations.
Handting BLQ Values
BLQ values flanked by measurable concentrations in the concentration versus
time profiles are commonly handled by three different approaches: Ï) they can be
discarded (set as missïng), 2) set at ½LLOQ, or 3) set to zero. There does not appear
to be a generai consensus as to which approach is best, as long as the method chosen
is justified and consistently applied withïn the PK methodology. According to
simulations performed by Stuart L. Beal (Beal 2001), setting the BLQ values as
missing is the least biased method when applying compartmental and population PK
models to data. Since it is erroneous to fit a value of zero using compartmentai
methods the BLQ values were set to missing for the compartmentai and population
PK analyses presented in this thesis. In addition, when faced with a sparse sampling
design, Beal suggests that using ½LLOQ could be a useful approach. Thus, for the
noncompartmental PK analysis presented in this thesis, BLQ values (< 1 ng/mL)
flanked by measurable concentrations were set to ½LLOD or 0.5 ig/L. The
alternative approaches of setting BLQ values as missing may overestimate the extent
of exposure (AUC) in a sparse sampling situation and setting BLQ values at zero will
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incorporate a negative bias since values flagged as BLQ values are actually
somewhere between zero and the LLOQ (i.e. could neyer be less than zero). The
impact of setting the BLQ values to ½LLOD will be covered in more detail in
Chapter 3, which presents the noncompartmental resuits.
Noncompartmentat Pharmacokinetics
The noncompartmental PK analyses were performed using PhAST® (Phoenix
1999) validated software. The maximum observed concentration, Cmax, was
obtained directly from the observed concentrations versus sampling times. The
extent of exposure from O to 2 hours postdose, AUC02, was calculated for ail dose
groups even though in most cases only 2 postdose concentrations were availabie.
Parameters AUC0, kel and t½ could flot be determined due to the sparse sampiing
and lack of terminal elimination in the profiles.
AUC02 was calculated using the linear trapezoid method. For some profiles,
a log-iinear approach may have been applicable due to apparent mono-exponentiai
decreases in concentration within certain intervals. However, assuming first-order
elimination, the linear trapezoidal rule tends to underestimate areas of increasing
concentrations, and overestimate areas of decreasing concentrations. The AUC
calculation using the linear trapezoid method was therefore deemed adequate for
comparative purposes for ail profiles in the current study, and was consistentiy
applied as follows (Gabrielsson and Weiner 2000):
n
AUC02 = Z (C + C+1)/2 .
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where C denotes the jth concentration and At denotes the time interval between the
C and C+1 concentrations. AUC02 represents the area under the curve from zero
until the tast measurable concentration at 2 hours postdose.
The Cmax and AUC parameters were compared for evidence of trans
resveratrol acctimulation for single versus multiple doses, as well as for any apparent
differences in bioavailability between the two formulations. Median values were
presented due to the high variability (30-160 CV%) observed between the PK
parameters. Since the median represented the center value(s) of the specified dataset
arranged in sequential order, this method of data presentation was judged to be the
least influenced by very Iow or high values.
Compartnzentat Pharrnacokinetics
Compartmental PK was performed with Adapt II® and population PK with
IT2S®. These methods were chosen because they provide flexibility in model
design and because the concentrations were obtained under controlled clïnical
conditions at specified sampling times.
Parameter Estimation
Individual compartmental PK parameters were estimated with Adapt II®
software (D’Argenio and Schumitzky 1998) using maximum likelihood (ML)
estimation, which derives the maximum probability of obtaining observed
concentrations given the estimated parameters in the model. Ideally, parameter
estimation minimizes the difference between the observed and predicted
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concentrations. The weighted least squares method was used as a minimization
method:
= Z W1 (Y -
where O is the objective function, W is an applied weight, Y is the ith observed
concentration and is the corresponding predicted concentration. A weïght
inversely proportional to the variance was applied in order to account for the
variability in the data:
w1 = 1/ o2
where 2 represents the variance associated with the observed value Y1. The
observed concentrations associated with a higher variance were attributed a smaller
influence in the parameter estimations.
The variances associated with the observed concentrations were calculated as
follows:
2
= + iopei*YIi)2 (non-extrapolated concentrations)
2
= (&it2 + 1ope2*Y2iÏ (extrapolated concentrations)
where the intercept includes errors associated with the analytical limit of detection
and the siope includes errors associated with the observed concentration Y. Finally,
the residual variability which represents a percentage of the data that could flot be
explained by the PK model was calculated as follows:
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Resid1 (%) [‘5lopeI + t5nti/ Pil*lOO
Resid2 (%) = [tiilope2 nt2 / 121*1OO
where ti and J12 represent the mean observed concentrations for the non-extrapolated
and extrapolated concentrations, respectively.
Mode! Discrimination
Various compartmental PK models were tested to find the least complex
model that best predicted the observed plasma concentrations. The criteria used to
distinguish between competing models were the Akaike Information Criterion (AIC),
the estimation criterion value (ECV), residual variability, coefficient of determination
(R2), and visual inspection of individual profiles.
Population Pharmacokinetics
Once the final structural model was determined via compartmental methods,
population analyses were performed using the iterative two-stage method with 1T2S®
(Collins and Forrest 1995). The first stage defined the kinetic parameters via the O4’
minimization procedure (described above) for each animal. The second stage
estimated the population kinetic parameters by computing the parameter mean at the
end of each iteration. Population mean variance and covariance were estimated a
posteriori at various stages of the iteration process.
The groups that received the 12.5% trans-resveratrol cream were analyzed
separately from those that received the 19% trans-resveratrol cream, and population
parameters were derived for each formulation. Lag and delay parameters fitting the
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Day 14 concentration data were included in the models only for groups that received
the 19% trans-resveratrol cream.
The parameters associated with a lag time were estimated during the
preliminary iterative processes. Once robustly estimated, they were fixed for each
animal, and the population analyses were restarted.
Population Parameters
Means (CV%) were computed for ail parameters in the mode!. The apparent
clearance (CL/F), absorption haif-life (T½ka) and elimination haif-life (T½keI) were
calculated for each animal using fitted population parameters as follows:
CL/F: kel*Vc/F
T½ka: O.693/ka
T½keI: O.693/kel
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Attometric Scating
So far, a iimited amount of data has been published that describes the PK of
trans-resveratrol in animais. Therefore, mean trans-resveratrol concentrations
obtained from the iiterature (Asensi et ai. 2002) were fitted using a compartmental
approach with Adapt II® and the derived parameters were used for ailometric
scaling. Single doses of 20 mglkg trans-resveratrol solution was administered via
intra-gastric gavage to mice (0.02 kg weight), rats (0.25 kg) and rabbits (2.25 kg) and
mean concentrations were best described by a two-compartment PK model. Total
apparent clearance and volume of distribution were plotted against animal body
weights on logarithmic scales. A regression une was obtained and PK parameters
were extrapolated to humans with an approximate body weight of 70 kg.
The siope of the une was assumed to be independent of the route of
administration since the same relationship across species would be observed using
different routes of administration. Thus, the population apparent clearance (CL/F)
and volume of distribution (Vc/F) of trans-resveratrol derived after topical
application to rabbits was plotted on the graph and a new regression une was derived.
Again clearance and volume of distribution were extrapolated to humans (70 kg) and
also to mice (0.02 kg).
To derive an efficacious hypothetical dose in humans against HSV infection,
a target AUC was estimated using allometric data in combination with published
efficacy resuits in mice (Docherty et al. 2004). A 12.5% trans-resveratrol topical
cream was one of the formulations used in the mouse efficacy study. Although the
exact dose was not measured, the cream was applied to an area of approximately 1 to
3$
2 cm2. In the rabbit study, 4 mg of 12.5% trans-resveratrol cream, equivalent to a
dose of 0.5 mg, was applied to an area of 4 cm2. This corresponds to an estimated 1
to 2 mg of trans-resveratrol cream, equivalent to 0.125 mg and 0.25 mg doses, if
applied to an area of 1 to 2 cm2. These doses and allometric clearance ïn mice were
used to estimate a targeted AUC that would be representative of efficacy against
HSV:
AUC = Dose! CL/F
The AUC corresponds to the possible extent of cxposure required to inhibit HSV
infection. The topical dose in humans that corresponds to this AUC will be estimated
using the allometric clearance for topical administration in humans:
Dose = CLIF x AUC
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CHAPTER 3: RESULTS
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Noncompartmentat Pharmacokinetics
Plasma concentrations were first analysed using noncompartmental
pharmacokinetic methodology. This section presents exploratory data analyses,
noncompartmental PK parameter estimations, a bioavailabilïty assessment of the two
formulations tested and an analysis of the treatment of BLQ values in the
determination of the extent of exposure of trans-resveratrol.
Preliminary Observations
The initial step, prior to determining any pharmacokinetic parameters, was to
inspect the data by plotting the concentrations against sampling times. Individual,
mean and median linear profiles from the 12.5 mg TK dose group are presented in
Figure 3.1 due to this group’s comparatively richer sampling schedule:
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Figure 3.] — Individuat, Mean and Median Plasma trans-Resverntrol Concentrations
on Day 1 (Figure 3.]a), Dav 14 (Figure 3.lb) and Day 28 (Figure 3.lc) Afler
Multiple Topicat Administrations of 12.5 mg of 19% trans-Resveratrot cream for 28
Davs to 6 Rabbits
I
Figure 3.la
Individuel, Mean (—) and Median (- - -) trans-resveratrol Concentrations
12,5 mg TK Gose Group - Day 1
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Visual inspection of the profiles on Day 1 showed at least two peaks in the
systemic absorption of trans-resveratrol after a single topical dose. After an apparent
lag time in the systemic absorption evidenced by the lack of measurable
concentrations at 0.25 hours postdose, a first absorption peak occurred at
approximately 0.5 to 0.75 hours post dose, followed by an apparent decrease in
concentrations. At approximately 1.5 to 2 hours postdose concentrations increased
agaïn in what appeared to be the beginning of a second (or a third, as was the case for
one rabbit) absorption peak. The mounting concentrations at the end of the profiles
indicated that the drug had probably not been completely absorbed within the 2-hour
dosing interval; thus, the rate of elimination could not be determined.
The individual profiles for the TK dose group on day 14 are shown in Figure
3.lb below.
0.5 0.75 1
Tlme (heurs poeldose)
1.25 15 175 2
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Mean (and median) plasma concentrations were approximately 5-fold greater
on Day 14 than on Day 1. The 0.75-, 1- and 1.5-hour postdose samples obtained on
Day 1 enabled the observation of multiple peaks in systemic absorption (Figure la).
Multiple absorption peaks were not observed on Day 14, possibly due to the
collection of only two postdose blood samples at 0.5 and 2 hours. The sparse
sampling may have been insufficient to capture any multiple systemic absorption
peaks similar to those observed in the profiles on Day 1.
The more extensive sampling schedule of Day 1 was repeated on Day 28 for
the 12.5 mg TK dose group and the profiles are shown in Figure 3.lc below.
Figure 3.1 b
Individual, Mean (—) and Median (- - -) trans-resveratrol Concentrations
12,5 mg TK Dose Group - Day 14
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The profiles obtained for Day 28 also appeared to show multiple systemic
absorption peaks and a lag time in absorption for some rabbits similar to the profiles
on Day 1. In addition, higher concentration peaks were observed for some of the
animais compared to the profiles on Day 1.
In summary, there appeared to be evidence of multiple absorption peaks
within the two-hour sampiing interval, with slight differences between the single and
multiple dose profiles. However, the variability of the concentrations (CV% range
42 — 245) and sparse sampling conditions must be considered regarding any observed
differences.
Pharmacokinetic Parameter Estimation
Prior to commencing the preclinical study, simulations were performed to
predict Cmax values (Cmaxpred) for Day 1 after a single application of 0.5 mg, 2.5 mg
and 12.5 mg trans-resveratrol cream. These simulations were based on results
obtained after oral administration of trans-resveratrol in rats in a previous study
Figure 3.lc
Individual, Mean (—) and Median t- - -) trans-resveratrol Concentrations
12,5 mg TK Dose Group - Day 28
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(Marier et al. 2002). A linear dose-concentration relationship and a similar relative
bioavailability of the trans-resveratrol cream to that of orally administered trans
resveratrol were assumed. Cmaxpred values, as well as the actual Cmax and AUC02
observed at the end of the study, are presented in Table 3.1 below.
Table 3.1 — Noncompartmental Pharmacokinetic Paraineters (Range) of trans
Resveratroi in Plasma after Multiple Topical Applications of two formulations of
trans-Resveratroi Cream for 28 Consecutive Days to Rabbits
Median (range) Pharmacokinetic Parameters
Dose Groups
Cmaxpred* Cmax (igfL) AUC02t (ighfL)
(jig/L)
Day 1 Day 28 Day 1 Day 28 diff (%)
12.5% Cream
0.5 mg 6 4.63 4.85 3.58 5.13 43
(2—13) (2-9) (2-10) (2-12)
2.5 mg 30 9.65 19.9 9.72 15.8 63
(2—14) (2—86) (2—16) (1-115)
19.0% Cream
12.5 mg 150 4.93 8.49 5.20 10.3 98
(3-18) (2-49) (3-23) (3-25)
* Predicted Cmax concentrations for a single dose calculated prior to study start
BLQ values flanked by measurable concentrations set to ½LLOD (0.5 igfL)
Percent increase in AUC02 from Day 1 to Day 28
The observed median maximum concentration (Cmax) of 4.63 j.tgfL in the
0.5 mg dose group on Day 1 was comparable to the predicted Cmaxpred of 6 igfL and
the observed Cmax value of 4.85 tg/L on Day 28. The extent of exposure (AUC02)
after the first application on Study Day 1 (3.58 jtg h/L) was comparable to the value
observed on Day 28 (5.13 tg hJL), suggesting that there was minor accumulation of
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trans-resveratrol after multiple applications of 0.5 mg of 12.5% trans-resveratrol
cream.
For the 2.5 mg dose group the Cmaxpred value of 30 tg/L was flot reached on
Day 1 and the observed median Cmax increased from 9.65 jig/L to 19.9 jigfL after
multiple applications from Day 1 through Day 2$. A 63% increase in AUC02 was
also observed, perhaps indicating that some accumulation may have occurred.
For the 19% trans-resveratrol cream formulation (12.5 mg dose), the observed
median Cmax of 4.93 ag/L on Day 1 was significantly lower than the predicted value
of 150 tg/L. This result was comparable to the median Cmax of 4.63 tg/L in the
0.5 mg dose group, which had a 25-fold lower dose. Two factors had not been
considered when Cmaxpred values were simulated: 1) the different properties of the
two formulations, and 2) the quantity of cream applied for each dose level. These
factors will be discussed in more detail in Chapter 4.
The median AUC02 values on Day 2$ were approximately double the values
observed on Day 1, suggesting some accumulation of trans-resveratrol following
multiple applications of cream for 28 consecutive days. However, this trend was not
conclusive due to the similar ranges observed for this parameter on Days 1 and 2$
(3-23 and 3-25 tghfL, respectively).
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Bioavaflability Plots
The noncompartmental analysis appeared to demonstrate differences in the
bioavailability of the two topical formulations. Although the 19% trans-resvertrol
cream (12.5 mg) contained up to a 25-fold higher nominal dose than the 0.5 mg and
2.5 mg 12.5% formulation, a proportional dose-related increase in the rate and extent
of exposure was flot observed. Figures 3.2 and 3.3 represent a visual depiction of the
relative differences in systemic bioavailability between these two formulations.
Figttre 3.2 - Linear Plot of Cmax Normalizedfor Dose versus the Dose for the 0.5 mg
and 2.5 mg groups (12.5% trans-resveratrot cream) and tue 12.5 mg groups (19%
trans-resveratrot creain)
Dayl Day 28
40 40
.
E
I :
0.5 2.5 12.5 0.5 25 125
Dose (n) flee (n)
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Figure 3.3 - Linear Plot ofAUCo2 Nornializedfor Dose versus the Dose for ttze
0.5 mg and 2.5 mg groups (12.5% trans-resveratrol cream) and the 12.5 nzg groups
(19% trans-resveratrol cream)
Day] Day28
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The 19% trans-resveratrol cream appears to be less bioavailable than the
12.5% formulation, as illustrated by the comparatively lower dose-normalized rate
and extent of exposure on Days 1 and 28. It should be noted, however, that the
amount of cream applied was significantly less for the 0.5 mg and 2.5 mg doses
(4 and 20 mg per application, respectively) than the 12.5 mg doses (66 mg per
application). This larger amount of cream applied, and flot solely the percentage of
trans-resveratrol contained within, may have contributed to the apparent lower
bioavailability of the 19% trans-resveratrol cream. Factors that may have affected
trans-resveratrol’s bioavailability will be discussed in more detail in the Discussion
section.
These noncompartmental pharmacokinetic resuits should be interpreted with
caution due to the sparse sampling schedule and restricted analytical detection limit.
Cmax and AUC02 may flot have been adequately characterized for the groups in the
.
.
t
I
.
I
I
0.5 12.5
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Primary Phase where profiles were described by only two postdose samples. The
LLOD of 1 jig/L accounted for a large percentage of the median Cmax (5-22%) and
AUC02 (6-28%) calculations. Consequently, the noncompartmental pharmacokinetic
parameters presented above may flot have been robustly assessed.
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Treatment of BLQ Values
As discussed in Chapter 2, there are three generally accepted approaches to
handling BLQ values flanked by quantifiable concentrations: 1) set the BLQ values
as missing, 2) set them at ½LLOD or 3) set them at zero. The best approach in a
noncompartmental model is the one that calculates the extent of exposure (AUC02)
with the least bias. This bias may be demonstrated best by comparing AUC02
caiculations using ail three approaches with data from the 12.5 mg TK dose group,
which had the richest sampling schedule on Days 1 and 28. The data are shown in
Table 3.2 below.
Table 3.2 — Noncompartmental Pharmacokinetic ParanzeterAUC02 Using Three
Dtfferent Approaches for Handiing BLQ Values in the 12.5 mg TK Grottp (19%
trans-resveratrot)
AUC02 (fig h/L)
BLQ Treatment 12.5 mg TK group Median values
Day 1 Day 28
settozero 4.06 12.7
set to ½LLOD
(0.5 1g/L) 4.12 13.0
set as missing 4.69 25.6
Setting the BLQ values as missing for the 12.5 mg TK group significantly
impacted the total extent of exposure on Day 2$, accounting for approximately ½ the
area when compared to the other two approaches (25.6 versus 13.0 pghfL).
figure 3.4 compares the differences between AUC02 calculations in the
profile of one rabbit from the 12.5 mg TK dose group when BLQ values are set to
½LLOD and to missing.
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Figttres 3.4a and 3.4b: Effect oJBLQ Treatment on the Profile ofRabbit #20, ]2.5mg
TK Dose Group on Day 28
Fihure 14a
DLQ values ai 07h, 1, and 1.5 h set to /.LLOD
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The shaded area represents the total extent of exposure (AUC02) attributed solely to
setting the BLQ values as missing at 0.75, 1 and 1.5 hours post dose. AUC02 was
15.6 tgh/L when these BLQ values were set at ½LLOD and 39.5 .tgh/L when set as
missing.
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It should be noted that the sampling schedules did flot include blood draws
between 0.5 and 2 hours post dose (0.75, 1 and 1.5 hours) for three of the four dose
groups. If ail groups had multiple peaks and troughs similar to those observed in the
12.5 mg TK group, the AUC02 calculations for the three remaining groups may have
been inftated.
The approach judged the least biased was to set BLQ values flanked by
measurable concentrations to 1/2LLOD, or 0.5 ig/L. This approach appears to be the
least biased due to 1) the sparse sampling, 2) the high ftequency (47%) of BLQ
values, and 3) the observed decreases in the extent of exposure, possibly due to
multiple systemic absorption peaks as illustrated in Figure 3.1.
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Cornpartmental Pharntacokinetics
Plasma concentration data were also analyzed using compartmental
pharmacokinetic modeling. This section presents the resuits used to derive the final
structural model prior to population PK analyses.
Model Determination
The compartmental pharmacokinetic models were written as first-order
differential equations, and individual pharmacokinetic parameters were derived cising
maximum likelihood with Adapt II® software. The criteria used to discriminate
between models were the minimum Aikaike information criterion (AIC), estimated
criteria value (ECV), residual variability, maximum R2 and visual inspection of the
individual profiles. Various models were constructed and their capacity to fit the
observed data was evaluated. These resuits are summarized in Table 3.3 below.
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Table 3.3 - Derived (Median Value) and Calcttlated Paranzeters Used ta
Identtfy the Strttctu rai Compartmental Pharmacokinetic Modet afler Multiple
Topicai Applications oftrans-Resveratroi Cream to Rabbits for 28 Davs
Mode! Description AIC ECV Residj(%) Resid2(%) R21 R22
Reslk 1 cpt basic 19.4 0.686 22.1 52.2 0.627 0.395
Res2k 2 cpt basic 20.6 -0.678 19.1 30.1 0.746 0.487
Resla lcpt, llag, 12.2 -3.90 17.3 25.1 0.845 0.617
1 delay
Resld lcpt, 2 10.7 -6.62 18.4 16.9 0.903 0.723
!ags,
2 delays
Res3d lcpt, 3abs, 22.8 -3.62 17.6 31.4 0.907 0.630
2!ags,
4 de!ays
Note I: Cpt = compartment, lag = time lag to initial systemic absorption, delay = time Ing to second absorption peak,
Rcsid1 and Resid2 = residual variability for non-extrapolated and extrapolated concentrations, respectively.
Note 2: Models Resla and Resld included I cpt, 2 absorption peaks and 1 ka in the model.
Note 3: Values in bold represent the best value for that particular parameter.
The pharmacokinetics of a topically administered trans-resveratrol cream to
rabbits appears to be best described by the model Resld which produced the lowest
AIC and ECV values of 10.7 and -6.62, respectively. The amount of unexplained
variability of 18.4% (Resid1) and 16.9% (Resid2) was relatively low while the R2
values of 0.903 and 0.723 were comparatively high for the non-extrapolated and
extrapolated concentration data, respectively. In addition, visual inspection of the
individual profiles demonstrated good fits to the concentration data. Appendix 1
includes individual parameter estimates for this model as well as schematics of a!1
rejected models included in Table 3.3. The final mode! is depicted in Figure 3.5 on
the following page.
54
Figitre 3.5- Final Model defined by one skin and central contpartlnent and oiie rate
of absorption defined by iwo absorption peaks and distinct Iag and delay parameters
for eacÏz ofDay] and Day 28
Dose
The final one-compartmental model (Resld) includes skin and systemic blood
compartments, one rate of absorption defined by two absorption peaks, as well as
distinct lag and delay parameters for each of Day 1 and Day 28. “Dose” represents a
single application of cream followed by proportional quantities (x and l-a) of trans
resveratrol absorption through the layers of the skin. The compound is subsequently
absorbed (ka) into the systemic circulation (defined by Vc/F) and a time delay in the
absorption associated with the proportion (1-a) of trans-resveratrol defines a second
absorption peak through the skin. The plasma concentrations predicted by the model
are based on the volume of distribution (Vc/F) of the systemic circulation also
estimated by the model. The drug undergoes elimination from the central
compartment by a first-order rate constant of elimination.
cx 1 -cx
Ka Lag]
Ka Lag28
Ka Dekzv I
Ka Dekiv28
Kel
55
The final mode! was described in a FORTRAN file using differential equations:
dX]
= R(1)a-kaX1Z
t2 = R(1)(]-a)-kaX2ZI
= R(2)a-kaX3Z2
dX4
= R(2)(1-a)-kaX4Z3
= kaX]Z+kaX2ZJ+kaX3Z2+kaX4Z3—ketX5
where:
Z=O; IF (tiine > tag]) Z=]
Z]=O; IF (tirne> lag]+ detay]) Z1=]
Z2=O, IF (tirne> 1ag28) Z2=1
Z3=O, IF (tirne> 1ag28+ detay28) Z3=]
Vc1/F
R( 1) represents the doses applied from Day 1 to Day 27 and R(2) represents
the dose applied on Day 28. The amount of trans-resveratrol in each box is
represented by Xl to X5 and the flag parameters Z to Z3 code the lag and delay
parameters. Ai! BLQ values were set as missing for compartmental PK analyses.
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Population Pharmacokinetics
The sparse sampling conditions necessitated population PK analyses to
robustly determine the pharmacokinetic parameters. Median values of the final
mode! parameter estimates derived with Adapt II® were used as beginning priors for
the population PK analysis, performed using an iterative two-stage methodology in
IT2S®.
Population PK Parameter Estimates
The population parameters were evaluated separately for each formulation
and parameter estimates obtained from IT2S® using the final mode! are presented in
Table 3.4.
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Table 3.4 — Estinzated inean population parameters and their percent coefficient of
variationJr trans-resveratrol after multiple topicat applications of 12.5% or 19.0%
trans-resveratrol cream to rabbits for 28 consecutive days
12.5% trans-resveratrol 19% trans-resveratrol
cream cream
Parameters Mean CV% Mean CV%
(%) 5.00 72.2 13.9 39.3
Ka (h4) 0.122 36.3 0.185 33.4
Vc/F (L) 3.20 73.8 9.13 16.3
Ke! (h’) 7.51 42.6 8.49 19.9
CL/F (lAi) 21.5 86.7 75.3 8.4
T½ka (h) 7.06 81.4 4.26 41.9
T½kel (miii) 7.76 60.6 5.11 23.6
LagÏ (h) 0.15 60 0.19 36.2
Delayl (h) 0.38 138 1.80 4.12
Lagl4 (h) ... ... 0.25 60.7
Delayl4 (h) ... ... 1.42 44.4
Lag28 (h) 0.30 187 0.54 101
DeIay28 (h) 0.94 86 1.92 32.3
Note: CL/F, t½ka and t½kcI are calculated pharmacokinetic parameters
The two-absorption peak mode! produced good fits to the observed
concentrations after multiple topica! applications of trans-resveratrol cream to
rabbits. Individuai graphs for ail animais are presented in Appendix II and Individual
PK parameters are presented in Appendix III. The inter-individual variability (CV%)
of the population parameters obtained using IT2S® (Appendix III) was lower than
the variability of the individual parameters obtained using Adapt II® (Appendix II).
Goodness-of-fit (Figures 3.6 through 3.9) demonstrate a good correlation
between predicted and observed concentrations as wel! as balanced weighted
res iduaÏs versus observed concentrations.
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Figttre 3.6: 12.5% tra,zs-Resveratrol Creani Poptilatioiz Predicted versus Observed
Concentrations Using the Final Model in IT2S®
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Figure 3.7: 19.0% trans-Resveratrol Cream Population Predicted versus Observed
Concentrations Usiizg tite Final Modet in IT2S®
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Figure 3.8: 12.5% trans-Resveratrol Cream Weighted Residitaïs versus Observed
Concentrations Using the Final Modet ut IT2S®
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Figure 3.9: 19.0% trans-Resveratrol Creain Weighted Residitaïs versus Observed
Concentrations Using the Final Modet iiz IT2S®
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Attometric Scating
As detailed in the previous chapter, mouse, rat and rabbit mean trans
resveratrol concentration data from the literature (Asensi et al. 2002) were fitted
using a two-compartment model and PK parameters were estimated (the profiles and
relevant pharmacokinetic parameters are included in Appendix IV) and used in the
allometric results presented below. The allometric relationships for the peripheral
volume of distribution (Vp/F) and clearance (CIdIF) fitted by the two-compartment
model are also included in Appendix IV for information purposes.
Allometrïc PK Parameter Resuits
The estimated PK parameters versus animal body weights were plotted on
logarithmic scales and a line equation [Yi = intercept + Xi(slope)J was derived for
each parameter using linear regression analysis. The predicted apparent volume of
distribution (Vc/F) and clearance (CL/F) in humans were extrapolated from these une
equations as shown in Figures 3.10 and 3.11 below.
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figure 3. ]Oa Allometric Prediction of Volume of Distribution (Vc/f) in Htunans after
Oral (.,Adrninistration in tÏze Mouse, Rat and Rabbit
1000 Vc/F
Human
100
Rabbitj7
10
2 Rat•,
0.1 Mouse
0.01 0.1 1 10 100 1000
Weight (kg)
Coefficients:
b[0]=1 .0095951256
b[1]=1 .059139309
r 2=0,9728
The total apparent volume of distribution was plotted against the respective animal
body weights on logarithmic scale. A regression une was obtained and a volume of
distribution was extrapolated to humans with an approximate body weight of 70 kg,
as shown by the intersection between the regression and vertical lines on the graph.
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Figure 3. lOb AtÏoinetric Prediction of Volume of Distribution (Vc/F) in Hiunans after
Oral (.,Administration in the Mouse, Rat and Rabbit, and Topical 12.5% trans
Resveratrot Crewn (Â) and 19% trans-ResveratroÏ Cream (u) Administration to
Rabbits
t
10 Z,.
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The lune equations for the topical formulations were derived in two steps, and
were based on the assumption that the siopes were identical, or the same relationship
across species would be observed, for both oral and topical routes of administration.
First, the intercepts were calculated for each topical formulation using the respective
siopes (coefficient b[1J) from the oral data and the mean population parameters in
rabbits (Table 3.4). Second, derived une equations were used to extrapolate the
apparent volume of distribution of topically administered trans-resveratrol to humans.
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Figure 3. lOc . Atiometric Prediction of Volume of Distribution (Vc/F) ut Humons
after Topical 12.5% trans-Resveratrol Creain (À) and 19% trans-Resveratrol Cream
(.)Administration to Rabbits
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The arrows in the figure above indicate the extrapolated volume of distribution in
humans predicted for topical application of both formulations of trans-resveratrol
cream.
These steps were repeated in order to determine the total apparent clearance
in humans as shown in Figure 3.11.
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figure 3.lla : AlÏometric Predictio,z of Clearance (CLIF) in Humans afler Oral (.)
Adnzinistration in the Mouse, Rat and Rabbit.
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Figure 3.llb : Allometric Prediction of Clearance (CLJF) in Humans afler Oral (.,)
Administration in the Mouse, Rat and Rabbit, and Topical 12.5% trans-ResveratroÏ
Cream (À) and 19% trans-Resveratrol Cream (.)Adntinistratioit to Rabbits
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Figure 3. lic Attoinetric Prediction of Ctearance (CWf. in Humans afler TopicaÏ
12.5% trans-Resveratrol Cream (À) and 19% trans-ResveratroÏ Cream (.)
Administration to Rabbits
5
t
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The arrows in the figures above indicate the extrapolated total apparent clearance in
in htimans.
In summary, the volume of distribution and total apparent clearance PK
parameters predicted in humans after topical administration were calculated using the
following une equations:
12.5% tra,zs-Resveratrol Cream:
Vc/F = antilog [0.0836761 + (1 .845098 x 1.0591393)]
CL/F = antilog [0.9539366 + (1845098x095115299)]
19% trans-Resveratrot Cream:
Vc/F = antilog [0.538996872 + (1.845098 x 1.059139309)1
CL/F = antilog [1.498293147 + (1845098x095115299)]
0001 ODI 0.1 10 Io
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where human body weight = log(7Okg) = 1.845098. Allometric scaling PK
Parameter Resuits are presented in Table 3.5 below.
Table 3.5 Allometric Scaling PK Parameters
Species* Orait Topicait
intra-gastric
(20 mg/kg) 12.5% Cream 19% Cream
Volume of Distribution (VcJF) (L)
Mouse 0.12$ 0.0192 0.0549
Rat 3.86
Rabbit 20.8 3.20 9.13
Human 920 109 311
Clearance (CLJF) (L/h)
7.66 0.218 0.763Mouse
Rat 71.3
Rabbit 760 21.5
Human 17031 511
_________________________
* Body Weights: Mouse = 0.02 kg, Rat = 0.25 kg, Rabbit = 2.5 kg, and Human = 70kg
Fitted (motise, rat and rabbit) and extrapolated (human) PK parameters (figures 3.10 and 3.11)
Fitted PK parameters for rabbit (shown in Table 3.4); mouse and human parameters extrapolated (Figures 3.10
and 3.11)
75.3
1792
67
Predicted Topical Dose in Humans
Previous resuits from the mouse efficacy study demonstrated that applying a
12.5% trans-resveratrol cream significantly inhibited HSV lesions (Docherty et al.
2004). Using the extrapolated apparent clearance of 0.2 18 Lfh in mice for this
formulation, an efficacious AUC could be estimated:
AUC = Dose! CL/F
= 0.125 mgI 0.218 L/h
= 0.573 mgh!L
Assuming linear pharmacokinetics, it follows that a dose of 0.25 mg would double
the effective AUC to 1.15 mghfL. In addition, the cream was applied every 3 hours
in the mouse study, corresponding to possible average concentrations (Cave) of
0.19 1 mcgfL to 0.382 mcglL in mice.
The efficacious AUC is the theoretical target for effective HSV inhibition in
humans. The topical dose in humans can be estimated using the extrapolated CL/F in
humans for the 12.5% trans-resveratrol formulation:
Dose in Humans = AUC x CL/F
=0.573 mghfLx 511 LIh
= 292 mg
Simulations were performed using a 300 mg topical dose of 12.5%
trans-resveratroÏ, an apparent clearance of 511 L/h and volume of distribution of
109 L in humans: Due to the long absorption rates of trans-resveratrol administered
as a cream formulation some accumulation is expected.
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figures 3. 12a — 3. 12d: Simulations in Humans usi;tg the Final Modet wittt Vaiying
ka (Ït’) and alpha (%) after 300 mg trans-resueratrol topical doses 0112.5% trans
resveratrot creain, Every Two Hours for a Total ofFive Applications
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Figure 3.12a: ka OE2h1; alpha = 10% Figure 3.12b: ka = 0.lh’; alpha = 5%
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Figure 3.12c: ka = 0.05h1; alpha = 10% Figure 3.12d: ka = 0.1h’; alpha = 25%
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Four scenarios were simulated using the final model with varying
combinations of trans-resveratrol absorption rates (ka) and the proportion of drug
absorbed in the first absorption peak (alpha). The vaLues chosen for these parameters
Time (hours)
10
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were based on the population PK resuits obtained for the 12.5% trans-resveratrol
cream in rabbits (Table 3.4). The highest predicted plasma trans-resveratrol
concentration of approximately 25 mcg/L in humans was observed after simulating 5
cream applications using an absorption rate (ka) of 0.2 W’ (Figure 3.12a).
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CHAPTER 4: DISCUSSION
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Pharmacokinetic Modeting
A compartmental model was designed to describe the pharmacokinetics of
trans-resveratrol after multiple topical applications of two cream formulations.
Multiple peaks observed in some of the profiles were pivotai for designing the final
model. Given the high variability of the plasma concentrations obtained ftom a
sparse sampling schedule, the use of population PK methodology in IT2S®
(Appendix III) gave more robttst estimates of the model PK parameters than Adapt ®
(Appendix I).
Multiple topical administrations of trans-resveratrol appeared to be well
described by a two absorption peak mode!. Individua! profiles showed increased
plasma concentrations at the end of the profiles, possibly due to a second absorption
peak. The PK of trans-resveratrol was characterized by a one compartmental model
with linear elimination. Although glucuronidation and 13-glucuronidase cleavage of
trans-resveratrol is theoretically possible in rabbits (Dulik and Fenselau 1987; Davies
and Morris 1993), enterohepatic circulation governed by bile release, cleavage and
intestinal reabsorption was considered unlikely within the 2 hour postdose interval
where the second peak occurred. This assumption is supported by previous resuits
which have shown that peaks due to trans-resveratrol enterohepatic recycling
appeared on average approximately 4 hours after intra-gastric administratïon in rats
(Marier et al. 2002).
Population PK parameters for trans-resveratrol in rabbits after multiple doses
of 12.5% trans-resveratrol cream was characterized by a high clearance (CL/F) of
21.5 L/h, a long absorption haif-life of 7.06 hours and a short elimination haif-life of
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7.76 minutes. Population resuits for the 19% trans-resveratrol formulation was
similar, and was characterized by a higli clearance (CLIF) of 75.3 Lfh, an absorption
half-life of 4.26 hours and an elimination half-Ïife of 5.11 minutes. The
pharmacokinetics thus appeared to be characterized by “flip-flop” kïnetics where the
absorption haif-life is much longer than the elimination half-life (Rowiand and Tozer
1992). The siope of the terminal phase of the concentration-time profile is
representative of drug absorption rather than elimination haif-life of the drug. The
occurrence of elevated plasma concentrations on Days 14 and 28 compared to those
observed after a single application of cream on Day 1 may therefore have been a
reflection of a long process of cutaneous and systemic trans-resveratrol absorption
after multiple daily doses. The fifth and last dose of trans-resveratrol cream on Day
13 or Day 27 was approximately 16 hours prior to the collection of the predose
samples on Days 14 and 28. This 1 6-hour interval between doses corresponds to an
estimated 123 to 188 elimination haif-lives based on the estimated T½keI of 7.76 and
5.11 minutes for the 12.5% and 19.0% formulations, respectively. From the
literature, in vivo data obtained after topical application of norephedrine, for example,
appeared to be characterized by “flip-flop” kinetics (Riegelman 1974; Roberts et al.
1999). Absorption of drug through the skin was described using first-order kinetics
with a first-order constant rate of absorption (time’).
Cutaneous absorption processes of trans-resveratrol through the skin after
topical application is cunently unknown, however, delays in absorption may
represent changes in permeability due to solute-skin interactions, such as possible
binding of the active compound to the stratum comeum or subcutaneous fat, where it
may be slowly released into the capillaries for days or weeks after initial application
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(Riviere 1993; Smith et al. 1999). A portion of the compound that binds to the
stratum corneum may be lost by exfoliation, hence neyer penetrate the skin layers to
the capillaries. In addition to capillary uptake, altemate processes of cutaneous
removal may occur such as uptake into the Iymphatic circulation and deep dermal
penetration, by-passing the capillaries and cutaneous metabolism. Partitioning
effects and diffusion of the solute through heterogeneous membranes defining the
tayers of the skin may also resuit in time-dependent changes in permeability (Roberts
et al. 1999). Improved percutaneous absorption is generally observed with increased
stratum corneum reservoir concentration. These possible solute-skin interactions and
skin reservoir effects may be complex and cannot be accounted for in detail using a
simplified first-order pharmacokinetic model.
The elimination rate constants may not have been robustly assessed in this
study; however, a short plasma eÏiminatïon half-life was flot unexpected based on
data in the literature. An elimination haïf-life of approximately 15 minutes had been
reported after i.v. administration of trans-resveratrol in rabbits (Asensi et al. 2002)
and also after p.o. administration in rats (Juan et al. 2002) and 3.74 minutes after i.p.
administration in rats (Zhu et al. 2000).
The high variability inherent to the concentration data and PK results may
have occurred predominantly from inter-animal variability, as well as the variability
in the application of the dose and skin treatments such as shaving the site. In
addition, washing with soap between doses from Day 10 to Day 2$ might have
affected the barrier integrity of the stratum corneum. Variability was also introdticed
by using extrapolated concentrations between the LLOQ and LLOD which may have
increased the probability of fitting analytical “noise”.
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Potentiat factors Affecting BioavaiÏabitity
J. Amotmt of Creani Applied Fer Dose
Low and mid dose groups (4 mg and 20 mg of 12.5% trans-resveratrol cream)
gave the highest dose-normalized Cmax, possibly due to factors such as the thïclmess
of the applied layer, evaporation effects, amount of trans-resveratrol in the cream and
hydration effects. The amount of cream applied to the site can affect drug delivery
(Flynn 1993). Evaporation of excipients begins immediately after topical
application, condensing the concentration of trans-resveratrol and enhancing its
penetration through the skin surface. When 4 mg and 20 mg of 1 2.5% trans
resveratrot cream and 66 mg of 19% trans-resveratrol cream was applied to a 4 cm2
area, the thickness of the layers varied at each dose level. The molecules at the top of
the thickest layer of cream (66 mg) must diffuse across a greater distance to reach the
skin surface, potentially delaying cutaneous penetration. The rate of condensed
trans-resveratrol formation is greatest in the thinnest layer (4 mg), since the ratio of
evaporated material to trans-resveratrol is small; however, a residue may form
quickly, impeding drug delivery.
2. Washing Solution between Applications
In the preclinical rabbit study, washing the site between dose applications was
important in order to remove any residue which may impede cutaneous absorption of
a subsequent dose. Water was initially deemed insufficient to remove this residue
and a soap solution was introduced on Day 10. Washing the skin with a soap
solution, however, could have extracted lipids from the stratum corneum, which
decreases its barrier properties (Pugh 1999). A relative bioavailability factor had
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been added to the final population PK model in order to account for possible
differences in systemic absorption due to this change in procedure but the overali
quality of fit did not improve (resuits flot shown).
3. Concentration ofApplied Solute
Increasing the concentration of appiied solute to the skin appears to increase
percutaneous penetration up to a certain point where a plateau may be reached
(Rougier et al. 1999). Percutaneous penetration of trans-resveratrol after application
of the 19% formulation may have been increased compared to the 12.5% cream;
however, corresponding increased plasma concentrations were flot observed.
Precipitation of the active compound out of the excipient can hait drug delivery. The
19% trans-resveratrol cream contains 6.5% iess water than the 12.5% cream. This,
combined with a higher concentration of active compound, may increase the risk of
trans-resveratrol precipitation out of solution, making drug delivery unsustainable. In
addition, skin hydration generally appears to enhance drug permeation especiaily
across the stratum comeum barrier, which favors the higher water content in the
12.5% formulation.
Tdeaily, a trans-resveratrol cream formutated to treat HSV infections should
produce an effective trans-resveratrol concentration in the basai epidermis iayer with
minimal systemic exposure. Plasma trans-resveratroi concentrations observed after
topicai application of both creams confirm that the compound was able to diffuse
through the skin layers and reach the basal epidermis, where active HSV replication
occurs, and beyond. Although trans-resveratrol plasma concentrations were
measured after topical application of both cream formulations, it remains impossible
to determine whether an effective trans-resveratrol concentration was reached in the
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epithelial celis at the basal epidermis. In addition, the 12.5% trans-resveratrol cream
at a lower trans-resveratrol dose per application than the 19% formulation was shown
to be effective against HSV lesion formation in vivo in mice, which may favor the
former formulation (Docherty at al. 2004).
Attometric Scating
Allometric scaling from the current in vivo preclinical data presented in this
thesis and data obtained from the literature (Asensi et al. 2002) was used to
extrapolate the apparent total clearance of oral and topical trans-resveratrol
administration in humans. A one-compartment model with multiple absorption peaks
best described the PK of trans-resveratrol after topical application while a two
compartment model best described the mouse, rat and rabbit mean trans-resveratrol
concentrations reported in the Asensi study. The apparent bi-exponential elimination
exhibited by the mean concentration profiles could be attributed to the high
variability (CV 30-50%) observed for the mean concentrations at the end of the
profiles (Asensi et al. 2002). Individual concentrations were not provided, however,
possible BLQ values at the end of the profiles could have accounted for this high
variability and also resulted in lower mean concentrations at the end of the profiles.
In addition, a 1 -compartment mode! best described the PK of trans-resveratrol in
humans (n = 3) after a single oral 1000 mg trans-resveratrol dose (Marier 2003).
A good coefficient of correlation (R2 = 0.9985) was observed for oral
clearance in mouse, rat and rabbit. The high apparent oral clearance predicted in
humans (17031 L/h) may be due to the 1-hour plasma collection period used in the
preclinical study following i.g. administration of 20 mglkg trans-resveratrol solution
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(Asensi et al. 2002). In a previous study conducted in healthy human volunteers, an
apparent clearance of approximately 1800 L/h was calculated using
noncompartmental methods after a 1000 mg trans-resveratrol oral dose (unpublished
data). In that study, plasma was collected over 24 hours; however, all profiles were
near or below the limit of quantitation at 12 hours post dose. Individual profiles
showed evidence of multiple absorption peaks andlor enterohepatic circulation due to
decreases and subsequent increases in concentrations as late as 4 hours after the
initial absorption peak. Population compartmental analysis of these results atso
predicted extensive trans-resveratrol oral clearance of 2835 LIh and approximately
33% of the drug undergoing enterohepatic circulation (EHC) (Marier 2003). In
support of possible EHC in humans, trans-Resveratrol EHC has been clearly
demonstrated in rats by use of a linked-rat mode! (Marier et al. 2002). As a result,
the elimination of trans-resveratro! may flot have been adequately characterized
within the short 1-hour sampling period in the previous work by Asensi et al. since
enterohepatic circulation would have occurred later.
We estimated that a 300 mg trans-resveratrol dose in humans (12.5% trans
resveratrol cream) would be required to produce the estimated effective plasma AUC
of 0.573 tgWL for the treatment of HSV. Simulations in humans of a 300 mg trans
resveratrot topical dose applied every 2 hours for 5 applications predicted plasma
concentrations up to a maximum of approximately 0.025 jag/mL (25 tg/L), a
concentration well below the in vitro effective range of 25 — 50 tg/mL (Docherty et
al. 1999). Similarly, the concentration range of 0.000191 — 0.000382 tg/rnL
estimated to have been reached in the mouse efficacy study (Docherty et al. 2004)
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was also well below the in vitro effective range. The authors of this preclinïcal study
note however, that the needle burr used to induce HSV infection may have disrupted
the barrier function of the stratum corneum potentially increasing treatment efficacy
compared to models with an intact stratum corneum. Nevertheless, at tians
resveratrol plasma concentrations below the in vitro effective range, topical
application of 12.5% trans-resveratrol cream appeared to inhibit HSV replication in
mice in vivo.
Cons idering that plasma concentrations are in equilibrium at the biophase, the
predicted high trans-resveratrol topical dose of approximately 300 mg in humans may
support the current hypothesis in the literature that suggests a possible
pharmacological activity of trans-resveratrol conj ugates. In another study,
simulations in humans were performed to predict effective steady state plasma
concentrations after oral administrations of trans-resveratrol (Marier 2003).
Potentially toxic oral doses of trans-resveratrol (1500 mgfkg b.i.d.) were required to
prodtice average plasma concentrations (Cave) of trans-resveratrol within the target
in vitro effective range of 10 — 20 llmol/L (2.28 — 4.56 jig/mL). However, assuming
that both trans-resveratrol and its glucuronide are pharmacologically active,
simulations predicted that oral doses of only 25 mg/kg b.i.d. would be effective.
That trans-resveratrol conjugates may be pharmacologically active has also
been proposed in other publications reporting low trans-resveratrol bioavaïlability
and extensive metabolism (Kuhnle et al. 2000; Asensi et al. 2002). Examples of
other drug conjugates that exhibit pharmacological activity include the morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G) morphine conjugates
(Hasselstrom and Sawe 1993). Interestingly, antioxidant properties have been
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reported for the conjugates cf quercetin, a flavonoid found in foods such as fruits,
vegetables, nuts and seeds (Morand et al. 1998; Manach et aI. 1998). Although
metabolic activity in the skin appears to be much lower than the activity in the
intestine or liver, drug conjugation in human skin has been reported (Hotchkiss
1998). In addition, topical application cf 8 and 16 imol resveratrol to shaved dorsal
skin cf female mice induced UDP-glucuronosyttransferase in the epidermis layer by
150 and 100%, respectively (Szaefer et al. 2004). These resuits support the
hypothesis that resveratrol may undergo glucuronidation in the skin prier te reaching
the systemic circulation.
The tepical 300 mg trans-resveratrol dose in humans reported above was
estimated with the assumption that the systemic availability of mouse and human
skin is similar. It should be noted that species-specific percutaneous absorption has
been reperted in the literature (Wester and Maibach 1993). In one study, human skin
appeared te be a more efficient barrier than mouse skin for a topically applied tea
pelyphenol EGCG (Dvorakova et al. 1999). The skin of cemmon Ïaboratory animais
such as rats and rabbits tends to be more permeable than human skin, while the
weanling pig and monkey appear te be better predictors cf human in vivo absorption.
Species-specific dermal cenjugation reactions in vitro have aise been reported for the
pesticide propoxur, where glucuronides and sulfates were detected in equal amounts
in pig skin, whereas only sulfates were detected in human skin, and glucuronides
were predominant in rabbit skin with only miner amounts of sulfides (van de Sandt et
al. 1993). Human predictiens scaled from preclinical percutaneotts absorption data
may therefore have limited applicability due te species-specific dermal
characteristics.
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future Work
trans-Resveratrol’s path through the skin layers prior to capillary absorption is
currently unknown. For toxicology purposes, measurement in plasma is important;
however, measurement in the skin, especially human skin, may be more informative
to predict local skin efficacy. Nevertheless, the current resuits from this study
confirmed that trans-resveratrol did cross the skin layers and reached the basal
epidermis where active HSV replication occurs. Radiolabelled methods that
characterize the permeability barrier of the human skin in vivo or track the
radiolabeled compound through the skin might be helpful to establish the fate of
trans-resveratrol after topicat application (Pirot et al. 1997). This would allow the
determination of the possible binding affinity of trans-Resveratrol to the stratum
comeum. The quantity of active compound penetrating through the skin layers may
be predicted from the amount measured in the stratum cornetim reservoir
approximately 30 minutes after topical application (Rougier et al. 1983) Rougier
suggests that the relationship between the amount in the stratum corneum and
percutaneous absorption is defined by a paraboÏic curve that may be independent of
animal species (Rougier et al. 1999). If a measurable quantity of compound is
present in the stratum corneum after application, tape-stripping methods used to
quantify these amounts may circumvent the use of radiolabeled compounds in
humans. Tape-stripping involves multiple site applications of an adhesive tape
foÏlowed by abrupt removaÏ. If the stratum corneum is the rate-limiting step in
absorption, quantification of drug concentration in this barrier may provide an
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estimate of the rate and extent of absorption to the lower skin layers (Naik et al.
1999).
Measurement of the stratum corneum reservoir may also be a good predictor
of efficacy, as was possibly demonstrated for the topical drug iododeoxyuridine
against HSV lesion reduction in vivo in the guinea pig (Sheth et al. 1987). Sheth et
al. appeared to show that dosing ftequency had an effect on the iodedeoxyuridine
stratum corneum concentration and corresponding efficacy. A plateau in efficacy
and stratum corneum AUC was reached at a dosing frequency of 3 applications per
day. Thus, cutaneous pharmacokinetics can possibly examine factors that influence
topical bioavailabilïty of various trans-resveratrol formulations by predicting the
concentration of trans-resveratrol in the target basal epidermis. Another method
estimated concentrations of free drug at the target site (C*) based on experimentally
determined in vitro flux data and topical in vivo efficacy (Mefita et al. 1997). A good
correlation was observed between predicted C and in vivo antiviral effïcacy of
acyclovir against HSV-l infections using a hairless mouse model (Patel et al. 1996).
Allometric scaling resuits in this thesis may support the cunent hypothesis
suggesting that trans-resveratrol conjugates may play an active role in producing
desired pharmacological effects. Thus, determining a possible pharmacologïcal role
of trans-resveratrol conjugates against HSV replication may be a valid hypothesis for
future research.
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CHAPTER 5: CONCLUSION
$3
As far as we know, this is the first study that characterized the PK of trans
resveratrol after multiple topical applications in rabbits. The 12.5% trans-resveratrol
formulation appeared to be more bioavailable than the 19.0% formulation. A
population PK mode! characterized by two absorption peaks was developed and
population PK parameters were determined for two trans-resveratro! cream
formulations. The PK results presented in this thesis may support current
development of an effective topical trans-resveratrol cream against HSV infection.
A topical dose in humans was predicted using allometric scaling and
simulations predicted possible trans-resveratrol plasma concentrations after multiple
topical applications of 12.5% trans-resveratrol cream. Predicted plasma
concentrations were lower than effective in vitro concentrations, supporting research
into estimating trans-resveratrol’s concentration in the local target area in the skin as
we!l as investigating possible activity of trans-resveratrol sulfate and glucuronide
conjugates against HSV replication.
$4
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Appendix I — Schematic Representation ofSome ofthe Rejected Compartmentat PK
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Appendix II - Individuat fitted () (Final Modet) vs observed(.,) trans-Resveratrol
Concentrations versus Time Following Multiple Top ical Administrations of 12.5%
trans-Resveratrol CreamJr 28 Consecutive Days to 12 Rabbits
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Appendix IV — figure 1: Mean transResveratroÏ Concentratio,zs (Asensi et al. 2002)
Fitted witÏz a Two Compartmental PK ModeÏ iiz Adapt II® afler Intra-gastric
Administration of20 mg/kg trans-Resveratrot Soit ttion to Rabbit, Rat and Mottse
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Appendix IV — Figttre 2: AÏÏonzetric Scating Resuits for PeripÏierat PK Parameters
fitted tising û Two Compartment Mode! in Adapt II® for Mottse, Rat, and Rabbi,’
Mean Concentration Data and ExtrapoÏated to Hurnans
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